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ScienceDirectTo enter into airway epithelial cells, influenza, parainfluenza-
and coronaviruses rely on host cell proteases for activation of
the viral protein involved in membrane fusion. One protease,
transmembrane protease serine 2 (TMPRSS2) was recently
proven to be crucial for hemagglutinin cleavage of some human
influenza viruses. Since the catalytic sites of the diverse serine
proteases linked to influenza, parainfluenza- and coronavirus
activation are structurally similar, active site inhibitors of these
airway proteases could have broad therapeutic applicability
against multiple respiratory viruses. Alternatively, superior
selectivity could be achieved with allosteric inhibitors of
TMPRSS2 or another critical protease. Though still in its
infancy, airway protease inhibition represents an attractive
host-cell targeting approach to combat respiratory viruses
such as influenza.
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Introduction
On a global scale, seasonal influenza A and B viruses cause
around 3–5 million cases of severe illness each year
resulting in about 250 000–500 000 deaths [1]. The exist-
ing drugs directing the influenza neuraminidase (oselta-
mivir, zanamivir, peramivir and laninamivir) or M2 proton
channel (amantadine and rimantadine), show rather mod-
est clinical efficacy and established or potential resis-
tance. Besides, pandemic variants may at any time
emerge due to gene reassortment between human and
zoonotic influenza viruses and rapid virus spread in a
globalized society. Novel medications with an inventive
mode of action are urgently needed to treat or prevent
severe influenza infections in vulnerable populations [2].Current Opinion in Virology 2017, 24:16–24 A recent WHO BRaVe (Research needs for the Battle
against Respiratory Viruses) [3] report calls for host cell
targeting antiviral approaches, since these are anticipated
to exhibit a higher barrier for drug resistance. We here
focus on a new paradigm to combat influenza or other
respiratory virus infections, which is directed towards
airway proteases with an essential role in virus activation.
Complementary to our concise analysis, some detailed
reviews were recently published elsewhere [4,5,6–8].
The influenza hemagglutinin as antiviral target
The influenza virus hemagglutinin (HA) mediates two
events in virus entry: (i) the HA globular head binds to
sialylated cell surface glycans resulting in virus endocy-
tosis; and (ii) the HA stem refolds at endosomal pH to
liberate the fusion peptide, causing fusion of the viral and
endosomal membranes and release of the viral genome
into the host cell cytoplasm. Hence, HA targeting entry
blockers may (i) interact with the HA receptor binding
site to inhibit virus attachment; or (ii) bind to the HA stem
region and inhibit fusion, for instance by preventing its
refolding at acidic pH. Design of broad influenza HA
blockers is anything but easy, given the high sequence
variability among HA subtypes; antigenic drift of HA;
different receptor usage of avian versus human influenza
viruses; and multivalent nature of the HA-receptor inter-
action. For instance, small molecule influenza fusion
inhibitors appear inadequate since they generally show
subtype specificity and rapid emergence of resistance [9].
An alternative and indirect strategy is to prevent the
proteolytic activation of HA by inhibiting the host cell
proteases responsible thereof. In influenza virus-infected
cells, HA is synthesized as the precursor protein HA0
(75 kDa), which assembles into a noncovalently linked
homotrimer. To obtain fusion capacity, HA0 needs to be
cleaved, by a cellular protease, into HA1 (50 kDa) and
HA2 (25 kDa). This enables insertion of the fusion
peptide (now located at the N-terminus of HA2) into a
negatively charged cavity, priming the HA for low pH-
dependent fusion [7].
Highly pathogenic avian influenza A viruses (HPAIVs) of
subtypes H5 and H7 possess a multibasic cleavage site
that is cleaved by ubiquitously expressed proteases,
explaining the systemic infections of these viruses in
avian species [7]. The multibasic cleavage site R-X-K/
R-R, with Arg at position P4, is processed in the trans-
Golgi network by furin and proprotein convertase (PC) 5/
6 [7], calcium-dependent serine proteases of the subtilisinwww.sciencedirect.com
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catalytic triad (Asp–His–Ser) as trypsin-like enzymes
[10]. For HPAIVs possessing a K-K/R-X-R motif, the
P4-Lys significantly suppresses cleavage efficiency by
furin and PC 5/6. These HAs are activated by type II
transmembrane serine proteases (TTSPs), more specifi-
cally mosaic serine protease large-form (MSPL) or its
splice variant TMPRSS13 [11].
In contrast, the HA0 proteins of human influenza A and B
viruses possess a cleavage loop with a monobasic (i.e.
single arginine) cleavage site. This feature is also present
in pandemic influenza A viruses, whether of H1N1
(including the viruses of 1918 and 2009), H2N2 or
H3N2 subtype. Inhibition of the HA-cleaving host cell
proteases induces production of non-infectious virions,
thus halting further virus replication. This type of inhi-
bitors could have two major strengths: (i) resistance is less
likely to develop since a host protein is targeted instead of
a highly mutable viral protein; and (ii) broad activity
against diverse respiratory viruses may be envisaged
since, besides influenza virus, several other respiratory
viruses rely on activation by similar proteases (see below).
Hence, these drugs might also be used to tackle outbreaks
by respiratory viruses for which no specific antiviral drugs
are available.
Host proteases involved in HA0 cleavage
activation
As summarized in Table 1, diverse trypsin-like proteases
(TLPs) are able to activate human influenza viruses in
vitro or in vivo. During virus propagation in chicken eggs,
HA0 cleavage is performed by blood clotting factor Xa in
the allantoic fluid [12], while in Madin Darby canine
kidney (MDCK) cell cultures, addition of trypsin is
needed for multicycle replication [13]. As for HA activa-
tion in the airways of infected persons, several TLP
candidate enzymes have been identified, but the picture
is still far from complete. A role is now well established for
transmembrane protease serine 2 (TMPRSS2), a member
of the TTSP family, which are integral membrane pro-
teins with an extracellular C-terminal serine protease
domain and an N-terminal cytoplasmic domain.
TMPRSS2-knockout (KO) mice were found to survive
infection with an H1N1 or H7N9 influenza virus that was
lethal in wild-type (WT) mice [14,15,16]. Furthermore,
a genome wide association study showed that patients
with higher TMPRSS2 expression levels had higher risk
for severe infections by the 2009 pandemic H1N1 virus
and increased susceptibility to influenza H7N9 [17]. For
the other circulating human influenza A subtype, H3N2,
the protease profile is less well defined and appears to be
strain-dependent. Compared to WT, TMPRSS2-KO
mice proved equally [15] or slightly less vulnerable
[14] to lethal H3N2 infection. A third H3N2 strain
was avirulent in TMPRSS2-KO mice but became lethal
after ten passages in mice [16,18]. Since the passagedwww.sciencedirect.com virus carried an N-glycosylation mutation at the bottom of
the HA stalk region, the loss of this glycan may alter the
accessibility of the cleavage loop and provide access to an
alternative host protease [18].
A second TLP candidate is the closely related TMPRSS4
enzyme [19,20]. When infected with an influenza H3N2
strain, TMPRSS2/TMPRSS4 double-KO mice displayed
lower morbidity and mortality, though showing some
body weight loss, pathology and processing of HA [21].
Thus, besides TMPRSS2 and TMPRSS4, additional
proteases are able to cleave and activate the HA of
H3N2 viruses. A possible explanation is provided by a
conformational difference seen in available HA0 crystal
structures [22,23]. In H3 HA0, the cleavage loop extends
from the protein surface, whereas in H1 HA0, the cleav-
age site is less exposed. Hence, H3 HA0 may be more
accessible to diverse proteolytic enzymes [21]. This
might allow for more efficient replication of the H3N2
virus, possibly explaining why the symptoms of H3N2
infections tend to be more severe compared to those of
the H1N1 subtype [24].
A role for human airway trypsin-like protease (HAT) was
proposed several years ago [25] but still awaits in vivo
verification in the existing and viable HAT-KO mouse
model [26]. A systematic analysis of the HA0 cleavage
pattern for 16 influenza A HA subtypes, was performed in
cell assays using coexpression of HA0 plus TMPRSS2 or
HAT protease [27]. Under these testing conditions,
cleavage by TMPRSS2 seemed, overall, more efficient
than that by HAT, although marked subtype dependence
was seen and neither of the two proteases was able of
activating all 16 HA subtypes. Analysis of the cleavage
site sequences of these 16 HAs did not point to any amino
acid as being an absolute determinant for recognition by
TMPRSS2 or HAT [27].
Besides TMPRSS2, TMPRSS4 and HAT, other mem-
bers of the TTSP family, namely matriptase [28–30],
DESC1 (differentially expressed in squamous cell carci-
noma gene 1) [31], MSPL (mosaic serine protease large-
form) and its splice variant TMPRSS13 [11,31] can medi-
ate cell membrane-associated HA0 cleavage of certain
HA subtypes. These investigations were performed in
HA0-expressing cells which were exposed to recombi-
nant protease or engineered to overexpress the protease
under study. The effect of matriptase was further dem-
onstrated in Calu-3 cells (a cell line derived from human
bronchial epithelia), in which matriptase gene knock-
down resulted in significant impairment of influenza
H1N1 replication [28]. In vivo investigations are hindered
by the fact that matriptase-KO mice are non-viable [32].
Additionally, secreted proteases like plasmin [33,34] and
kallikrein (KLK) types 5 and 12 [35] can perform H1 and
H3 HA0 cleavage [35]. Although all these proteases areCurrent Opinion in Virology 2017, 24:16–24
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Table 1
Experimental data on the role of airway proteases in the activation of influenza-, corona- and paramyxoviruses
Protease Virus In vitro evidence In vivo evidence
TMPRSS2 Influenza A and B virus The HA0s from H1N1, H2N2, H3N2 or
influenza B are cleaved in cells
overexpressing TMPRSS2 enabling
trypsin-independent replication
[25,36,66]. Knockdown of TMPRSS2 in
Calu-3 cells inhibits cleavage of H1N1 [67]
TMPRSS2-KO mice survive lethal
infection with influenza H1N1 or H7N9
[14–16]. In contrast, influenza B virus is
lethal in TMPRSS2-KO mice [37]
SARS, MERS and 229E
coronaviruses
The coronavirus S-protein is cleaved when
co-expressed with TMPRSS2
[31,62,64,68]
Metapneumovirus and
parainfluenzavirus
The viruses efficiently replicate in cells
overexpressing TMPRSS2 and their F
protein is cleaved [58,59]
TMPRSS4 Influenza A virus HA0 from H1N1 is cleaved in TMPRSS4-
expressing cells. Knockdown of
TMPRSS2 and TMPRSS4 reduces H1N1
virus replication [19–21]
H3N2 replication is significantly reduced
but not abolished, in TMPRSS2/
TMPRSS4-double KO mice [21]
HAT Influenza A and B virus The HA0s from H1N1, H2N2 and H3N2 or
influenza B are cleaved in cells
overexpressing HAT enabling trypsin-
independent replication [25,36,54,66]
This remains to be investigated in the
HAT-KO mouse model [26]
SARS and MERS
coronaviruses
The coronavirus S-protein is cleaved when
co-expressed with HAT [31], hence
activating the S protein for cell-cell fusion
[69]
TMPRSS13/MSPL Influenza A virus; SARS
and MERS
coronaviruses
The HA0s from subtypes H1, H2 or H3;
and HPAIV H5 and H7 with KKKR motif
(not recognized by furin), and S-proteins
from SARS or MERS coronavirus, are
cleaved when co-expressed with MSPL or
its splice variant TMPRSS13 [11,31]
This remains to be investigated in
MSPL-KO mice, which display abnormal
skin development [70]
Matriptase Influenza A virus Knockdown of matriptase in Calu-3 cells
leads to reduced growth of H1N1 virus [28]
Overexpressed HA0 from subtypes H1 or
H9 (with RSSR/RSRR motif) is cleaved
when cells are exposed to recombinant
matriptase [29,30]
These studies are hindered by the fact that
matriptase-KO mice are unviable [32]
DESC1 Influenza A virus; SARS
and MERS
coronaviruses
The influenza HA0s subtypes H1, H2 and
H3, and S-proteins from SARS or MERS
coronavirus are cleaved when co-
expressed with DESC1 [29]
KLK5, KLK12 Influenza A virus Exogenous KLK5 cleaves overexpressed
HA0 from subtypes H1 or H3, whereas
KLK12 activates subtypes H1 and H2 [35]
Plasmin Influenza A/H1N1, strain
A/WSN/33
A/WSN/33 neuraminidase recruits
plasminogen, which after conversion into
plasmin leads to HA0 cleavage [34]
Soluble serine
proteases, for
example tryptase
Clara
Influenza A virus Lungs from rats or pigs contain diverse
trypsin-like proteases which, when
isolated, cleave the HA0 protein of
influenza H3N2. The relevance for
infections of humans is uncertain
[33,71–73]
TMPRSS2: transmembrane protease serine 2; TMPRSS4: transmembrane protease serine 4; HAT: human airway trypsin-like protease; TMPRSS13:
transmembrane protease serine 13; MSPL: mosaic serine protease large-form; DESC1: differentially expressed in squamous cell carcinoma 1; KLK:
kallikrein.
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Figure 1
Catalytic triad
Exosite II
Exosite I
Asp189
Asp102
His57
Ser195
Current Opinion in Virology
Superposition of known TLP crystal structures: trypsin (pdb: 3MFJ, yellow); matriptase (pdb: 1EAX, cyan blue); DESC1 (pdb: 2OQ5, green); KLK5
(pdb: 2PSX, orange); and thrombin (pdb: 3RLW, grey). Residues shown in stick model represent the catalytic triad (in red font) or aspartic residue
in the S1 specificity pocket (in green font). Performed with PyMol Molecular Graphics SystemTM. Laporte et al. unpublished.able to activate influenza virus in cell culture, there is no
evidence yet confirming their role in the airways of
influenza-infected individuals.
In the case of influenza B virus, the HA0 activation
mechanism is largely unexplored. In cell culture, over-
expression of TMPRSS2 or HAT resulted in HA0 cleav-
age and multicycle replication of influenza B virus [36].
This disagrees, however, with the in vivo finding that
influenza B virus displays efficient HA0 cleavage and full
pathogenicity in TMPRSS2-KO mice [37]. Unlike influ-
enza A, influenza B virus does not absolutely require
exogenous trypsin to replicate in certain MDCK cell
lines, indicating that these cells express an as yet uniden-
tified protease that acts on the HA of influenza B but not
(or far less efficiently) on that of influenza A [38,39].
Inhibition of airway proteases as antiviral
strategy
All serine proteases mentioned above are classified as
trypsin-like proteases (TLP) since they cleave peptide
bonds after a positively charged amino acid (arginine or
lysine). This P1 specificity is linked to the presence of a
negatively charged Asp residue at the bottom of the S1
specificity pocket (Figure 1). As of today, crystal struc-
tures are available for matriptase [40], DESC1 [41] andwww.sciencedirect.com several kallikreins [42], but not for TMPRSS2,
TMPRSS4 or HAT. The crystallographic information
indicates a high degree of structural homology in the
active site regions of the TLPs, which contain the cata-
lytic triad His57, Asp102 and Ser195 (chymotrypsin num-
bering). Outside this catalytic domain, several exosites
exist with higher structural diversity and a critical role in
substrate binding and recognition [43]. Consequently,
active site targeting inhibitors have a higher chance of
possessing a broader activity spectrum, whereas exosite or
allosteric binding is preferred to develop highly selective
TLP inhibitors.
Proof-of-concept (pre)clinical evidence is already avail-
able, since the broad serine protease inhibitors aprotinin
and camostat suppress influenza virus replication in cell
culture and mouse models, through inhibition of serine
proteases involved in HA0 cleavage and inflammation
[44,45]. Moreover, aerosolized aprotinin (an approved
therapy in Russia) was shown to shorten symptom dura-
tion in humans infected with influenza or parainfluenza
virus [44]. However, aprotinin is a protein with unfavor-
able pharmacokinetics whereas camostat is a covalent
binder; both are non-specific protease inhibitors with
potential side-effects. To achieve agents with superior
potency and safety, specific inhibitors of the relevantCurrent Opinion in Virology 2017, 24:16–24
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Table 2
Described inhibitors for TMPRSS2 and related TLPs
Name and structure Ki (nM) in enzymatic assay Antiviral activity in cell culture References
TMPRSS2 HAT Matriptase Thrombin FXa
Peptidomimetic inhibitors
Inhibitor ‘92’ 0.9 1700 NA 20 50 Inhibits H1N1 and H3N2
replication in Calu-3 cells
[46]
Inhibitor ‘50 20 19 55 3.5 2.4 Inhibits H1N1 and H3N2
replication in HAT-expressing
MDCK cells
[47]
Inhibitor ‘10 NA 0.0084 0.000011 0.637 NA Inhibits H1N1 replication in
Calu-3 cells
[28,49]
Non-peptidomimetic inhibitors
Bromhexine 0.8 NA 59 >100 NA Nonea [52]
0591-5329 0.9 NA 75.3 >100 NA Nonea [52]
4401-0077 2.7 NA >100 >100 NA Nonea [52]
4554-5138 1.4 NA 78.3 >100 NA Nonea [52]
8008-1235 2.6 NA >100 >100 NA Nonea [52]
NA, not available.
a Laporte, unpublished data.airway proteases, particularly TMPRSS2, need to be
designed.
The classical type of protease inhibitors are peptidomi-
metic substrate analogues. TLP inhibitors with high
binding affinity are obtained by coupling a P1-ArgCurrent Opinion in Virology 2017, 24:16–24 mimicking moiety to a peptidyl portion with optimized
size and composition, to enable tight fitting in the active
site. Among two series of TMPRSS2 inhibitors containing
either a 4-amidinobenzylamide or a sulfonylated 3-ami-
dinophenylalanylamide, several analogues displayed Ki
values below 20 nM in an enzymatic assay withwww.sciencedirect.com
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best inhibitor (92 in Table 2) had a Ki value of 0.9 nM and,
interestingly, produced clear inhibition of HA0 cleavage
and virus replication in Calu-3 cells, which endogenously
express HA0-activating proteases like TMPRSS2. Inhib-
itor 5 (Table 2), which contains 4-amidinobenzylamide at
P1, proline at P2 and D-arginine at P3, was also nicely
active (Ki value of 19 nM) against recombinant HAT
enzyme, indicating that inhibitors with dual activity
against these two relevant airway proteases can be
achieved [47]. Unfortunately, compound 5 also produced
strong inhibition of the related TLPs thrombin, plasmin
and factor Xa, suggesting that the P2 proline substitution
entails reduced selectivity [47].
Besides this selectivity issue, the safety of serine protease
inhibitors largely depends on whether or not the binding
is reversible. The classical inhibitors show covalent bind-
ing to the catalytic serine, which is in most cases (pseudo-)
irreversible, for example with camostat [48]. Such irre-
versible protease inhibitors may pose a safety issue.
However, the matriptase inhibitor 1 (Table 2) possesses
a ketobenzothiazole moiety that forms a covalent yet
reversible bond with the catalytic serine [49]. This com-
pound caused a significant reduction of influenza H1N1
replication in Calu-3 cells [28]. Whether this can solely be
attributed to inhibition of matriptase is unclear, since the
effect of 1 on other relevant proteases like TMPRSS2 was
not reported.
An entirely different approach aims at developing exosite
binders or allosteric inhibitors [50,51]. Discovery of these
inhibitors requires high-throughput screening (HTS) or
fragment-based approaches, unlike the peptidomimetic
active site binders which can be rationally designed from
known peptide substrates. A biochemical HTS with
recombinant TMPRSS2 protein yielded five hit com-
pounds, including bromhexine, which is used as a muco-
lytic drug [52]. These hits (Table 2) displayed selectivity
for TMPRSS2 (i.e. poor to no activity against matriptase,
trypsin or thrombin) which, combined with their non-
peptidomimetic structure suggests that they could be
exosite or allosteric inhibitors. Bromhexine was shown
to suppress prostate cancer metastasis in a mouse model,
in line with the role of TMPRSS2 overexpression in
promoting prostate cancer metastasis [52]. As for influ-
enza, we evaluated all five compounds in virus-infected
Calu-3 cells but did not observe any inhibitory effect
(Laporte, unpublished data), indicating that hit-to-lead
optimization is still required.
Another factor to take into account is the compound’s
ability to permeate the cell membrane. For example, it is
unclear whether the influenza suppression by the poly-
peptidic (6 kDa) compound aprotinin occurs extracellu-
larly or, rather, after the compound has been internalized
[53]. Influenza HA0 cleavage can occur in the trans-Golgiwww.sciencedirect.com network during transport of newly synthesized HA0 along
the secretory pathway; or at the apical cell membrane
when virions are being released from infected cells; or
subsequently during entry into a new host cell [5,53].
TMPRSS2 is mainly localized in the trans-Golgi network
where it cleaves newly synthesized HA0. On the other
hand, since HAT mainly resides on the cell membrane
with its protease domain directed towards the extracellu-
lar space, this protease can cleave HA0 of both released
and incoming virus [54].
Potential for safe and broad spectrum antiviral
therapy
Despite the growing interest in host cell factors as a target
for antiviral intervention [55], possible toxicity is a logical
concern. This seems not verified for the TMPRSS2,
TMPRSS4 and HAT airway proteases since HAT,
TMPRSS2 and TMPRSS4 (single or double)-knockout
mice are perfectly healthy [21,56,57]. Matriptase however
is indispensable and ubiquitously expressed, with a
known role in the development of the epidermis, hair
follicles, and cellular immune system [32].
One unique benefit of blocking TMPRSS2 and related
airway proteases is that, besides influenza virus, several
other respiratory viruses could be targeted. TMPRSS2
was shown to activate the fusion proteins of some para-
myxoviruses (i.e. metapneumovirus [58], trypsin-depen-
dent parainfluenza subtypes and Sendai virus [59]). Like-
wise, for some human coronaviruses including the deadly
SARS and MERS variants [8,60,61,62], TMPRSS2
cleavage activates the viral spike (S)-protein at the cell
surface enabling cathepsin-independent host cell entry
[63,64]. The S-proteins of the MERS and SARS corona-
viruses were also cleaved when co-expressed with
DESC1 or MSPL protein [31]. There is also in vivo
evidence since camostat proved effective in protecting
mice against a lethal infection by SARS coronavirus [65].
Since an antiviral medication for these paramyxoviruses
and coronaviruses is currently lacking, broader-acting
airway protease inhibitors could be well suited to fill this
gap.
Finally, airway protease inhibitors could be combined
with more conventional antiviral drugs to obtain a syner-
gistic effect or reduce the risk of resistance. For instance,
the combination of oseltamivir with the serine protease
inhibitor BAPA (benzylsulfonyl-D-Arg-Pro-4-amidino-
benzylamide) was found to suppress influenza virus rep-
lication in human airway epithelial cells at remarkably
lower concentrations than treatment with each inhibitor
alone [36].
Conclusion
Trypsin-like proteases of the human airways represent
unique targets to suppress infections with influenza or
other respiratory viruses which rely on these enzymes forCurrent Opinion in Virology 2017, 24:16–24
22 Antiviral strategiestheir replication. The significance of TMPRSS2 is sup-
ported by recent proof, from mouse or clinical studies,
that this protease is essential for replication of influenza
H1N1 and H7N9 viruses. TMPRSS2 protease inhibitors
may act by two different mechanisms: strong yet, prefer-
ably, reversible binding to the active site; or interference
with an exosite or allosteric domain. An advantage of
active site binders would be the potential to suppress not
only TMPRSS2, but also other relevant airway proteases
including TMPRSS4 and HAT. The design of selective
inhibitors would be facilitated by a better insight into the
protein structures of these proteases. More research is also
needed to precisely define the protease cleavage profile of
human A/H3N2 and, particularly, influenza B viruses.
Whether used as mono- or combination therapy, these
airway protease inhibitors could represent a unique class
of host cell-targeting drugs with a broad spectrum of
antiviral activity.
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